DIABETES AND METABOLIC SYNDROME • HEART FAILURE • CANCER • DATA ANALYTICS • ENTREPRENEURSHIP

Entrepreneurship

DR. STOKES HAS FOUNDED THREE START-UP COMPANIES.

Makai Biotechnology is developing novel therapies for the treatment of heart failure. A new ion channel target in this disease has been identified, along with multiple effective compounds that regulate this target. Key animal model data show that the Makai therapeutic approach can both protect and reverse heart failure. Makai’s intellectual property portfolio includes awarded patents in Europe and the USA, and the company is poised to radically improve the global landscape of heart failure therapy.

Practical Biotechnology recognizes that cases of advanced non-small cell lung cancer (NSCLC) have some of the poorest outcomes for patients due to acquired tumor resistance to chemotherapy. Conventional courses of anti-cancer treatments lead to the emergence of cancer stem cells (CSC), which help the tumor maintain itself and develop resistance to chemotherapeutic drugs. Practical Biotechnology is developing therapeutic candidates to kill cancer stem cells and reverse tumor chemotherapy resistance in NSCLC, with a low side effect profile. Our therapeutic candidates are initially aimed at NSCLC and breast cancer. As a winner of the 2018 international ‘Freedom From Cancer’ Startup Challenge, with licensed intellectual property from UCLA, Practical Biotechnology has laid a compelling foundation for next-stage funding.

 Ohuku.ai is a data analytics and visualization company developing elegant biologically-inspired data processing, simulation and visualization methods to support the S&T, healthcare, and finance sectors. Our mission is to demystify complex data and democratize access to the power that these data hold using simulated organic life models. Ohuku has assembled an exceptional team of entrepreneurs, scientists, and NSF-funded data science experts. Ohuku has an  emerging IP portfolio at the PCT stage, and a prototype stock market visualization tool developed,